A Novel Multi-epitope Vaccine Against SARS-CoV-2 Variants of Concern Strains Applying Immunoinformatics Approaches

Background: The newly emerged coronavirus, SARS-CoV-2, the causative agent of the COVID-19 disease, appeared in Wuhan, China in December 2019 and led to the death of millions of people. The pandemic has increased the demand for effective vaccines and treatments worldwide. Due to the changes in the virus genome caused by mutation, variants with higher transmission ability and pathogenicity have emerged and raised excessive concerns about the efficiency of the developed vaccines. This study aimed to design a multi-epitope vaccine that targets the primary SARS-CoV-2 strain and its five variants of concern using immunoinformatics approaches. Methods: B-cell, cytotoxic T lymphocytes (CTLs) and helper T lymphocytes epitopes of the conserved and mutated SARS-CoV-2 surface glycoproteins were predicted using immunoinformatics approaches. These epitopes were attached utilizing appropriate linkers, and to provoke the immune response efficiently, the cholera toxin B subunit was added as an adjuvant. Results: Analyses by different bioinformatics softwares revealed that the designed vaccine’s high safety, stability, and efficacy. Conclusion: In this study, the vaccine designed by immunoinformatics tools showed specific reactivity to Toll-like receptor 4. Given the validation of other epitope-based vaccines, our vaccine might be capable of providing strong immunity in a wide range of populations.

[1]  Shaghayegh Haghjooy Javanmard,et al.  Vaccine design and delivery approaches for COVID-19 , 2021, International Immunopharmacology.

[2]  V. Lee,et al.  Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study , 2021, Clinical Microbiology and Infection.

[3]  Ahasanul Kobir,et al.  Immunoinformatics and molecular dynamics approaches: Next generation vaccine design against West Nile virus , 2021, PloS one.

[4]  Lakshmi Pinnaka,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants. , 2021, The New England journal of medicine.

[5]  E. Shin,et al.  SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern , 2021, Signal Transduction and Targeted Therapy.

[6]  Ravindra K. Gupta.  Will SARS-CoV-2 variants of concern affect the promise of vaccines? , 2021, Nature Reviews Immunology.

[7]  R. Darnell,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[8]  Jialu Zhang,et al.  Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies , 2021, Expert review of vaccines.

[9]  Jerome H. Kim,et al.  Vaccine development for emerging infectious diseases , 2021, Nature Medicine.

[10]  K. Schenke-Layland,et al.  Immune response to SARS-CoV-2 variants of concern in vaccinated individuals , 2021, Nature Communications.

[11]  Ravindra K. Gupta,et al.  The effect of spike mutations on SARS-CoV-2 neutralization , 2021, Cell Reports.

[12]  R. Walensky,et al.  SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities. , 2021, JAMA.

[13]  M. Biggerstaff,et al.  Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  H. Can,et al.  In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19 , 2020, Scientific Reports.

[15]  Ji-min Cao,et al.  SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development , 2020, Frontiers in Cellular and Infection Microbiology.

[16]  V. Thiel,et al.  Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.

[17]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[18]  M. Shokrgozar,et al.  In silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic Escherichia coli , 2020, Scientific Reports.

[19]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[20]  D. A. Jackson,et al.  Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity , 2020, Cell.

[21]  Shuwen Liu,et al.  Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.

[22]  Shahin Nazarian,et al.  An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study , 2020, Scientific Reports.

[23]  Md. Shahedur Rahman,et al.  Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach , 2020, Journal of biomolecular structure & dynamics.

[24]  Xuguang Li,et al.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.

[25]  Hermann Wätzig,et al.  Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control , 2020, Electrophoresis.

[26]  Fengxiang Wei,et al.  Epidemiology and Clinical Characteristics of COVID-19. , 2020, Archives of Iranian medicine.

[27]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[28]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[29]  Bishajit Sarkar,et al.  Exploiting the Reverse Vaccinology Approach to Design Novel Subunit Vaccine against Ebola Virus , 2020, medRxiv.

[30]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[31]  M. Barhoumi,et al.  In silico analysis and in vitro evaluation of immunogenic and immunomodulatory properties of promiscuous peptides derived from Leishmania infantum eukaryotic initiation factor. , 2017, Bioorganic & medicinal chemistry.

[32]  Lifang Zhang.  Multi-epitope vaccines: a promising strategy against tumors and viral infections , 2017, Cellular & Molecular Immunology.

[33]  Morten Nielsen,et al.  NetMHCpan 4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data , 2017, bioRxiv.

[34]  Bjoern Peters,et al.  BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes , 2017, Nucleic Acids Res..

[35]  Dima Kozakov,et al.  The ClusPro web server for protein–protein docking , 2017, Nature Protocols.

[36]  Bjoern Peters,et al.  TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates , 2016, Current protocols in immunology.

[37]  Wei Li,et al.  RaptorX-Property: a web server for protein structure property prediction , 2016, Nucleic Acids Res..

[38]  Wei Li,et al.  CoinFold: a web server for protein contact prediction and contact-assisted protein folding , 2016, Nucleic Acids Res..

[39]  Jiandong Shi,et al.  Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases , 2015, PloS one.

[40]  Arafat Rahman Oany,et al.  Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach , 2014, Drug design, development and therapy.

[41]  Darren R. Flower,et al.  AllerTOP v.2—a server for in silico prediction of allergens , 2014, Journal of Molecular Modeling.

[42]  Xiangguo Duan,et al.  Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model , 2014, Applied Microbiology and Biotechnology.

[43]  Y. Liu,et al.  Cholera toxin B subunit acts as a potent systemic adjuvant for HIV-1 DNA vaccination intramuscularly in mice , 2014, Human vaccines & immunotherapeutics.

[44]  Chaok Seok,et al.  GalaxyRefine: protein structure refinement driven by side-chain repacking , 2013, Nucleic Acids Res..

[45]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[46]  Jose Davila,et al.  Comparison of the Predicted Population Coverage of Tuberculosis Vaccine Candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a Bioinformatics Approach , 2012, PloS one.

[47]  Pierre Baldi,et al.  SOLpro: accurate sequence-based prediction of protein solubility , 2009, Bioinform..

[48]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[49]  Manfred J. Sippl,et al.  Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..

[50]  D. Flower,et al.  Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. , 2007, Vaccine.

[51]  Irini A. Doytchinova,et al.  BMC Bioinformatics BioMed Central Methodology article VaxiJen: a server for prediction of protective antigens, tumour , 2007 .

[52]  Sudipto Saha,et al.  Prediction of continuous B‐cell epitopes in an antigen using recurrent neural network , 2006, Proteins.

[53]  Morten Nielsen,et al.  Improved method for predicting linear B-cell epitopes , 2006, Immunome research.

[54]  John Sidney,et al.  Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.

[55]  Dieter Jahn,et al.  JCat: a novel tool to adapt codon usage of a target gene to its potential expression host , 2005, Nucleic Acids Res..

[56]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[57]  Yingdong Zhao,et al.  Application of support vector machines for T-cell epitopes prediction , 2003, Bioinform..

[58]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[59]  Liam J. McGuffin,et al.  The PSIPRED protein structure prediction server , 2000, Bioinform..

[60]  A. Suhrbier,et al.  Multi‐epitope DNA vaccines , 1997, Immunology and cell biology.

[61]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.